Highlights<\/p>\n
Healthcare Stocks are active before the London open because drug-pipeline disclosures, half-year reporting and transaction activity are making healthcare a company-led defensive theme, with GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n offering a useful current reference point. Same-day context includes July CPI at, Bank Rate at and an active August London corporate calendar. Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n place operational evidence ahead of broad sector enthusiasm. UK consumer price inflation rose to in July from in June, while the Bank of England kept Bank Rate at at its July meeting and continued to flag upside inflation risk from volatile energy prices. Healthcare has a same-day corporate-flow signal because ConvaTec trades ex-dividend on August, while the wider sector remains driven by product execution, pipeline evidence and the relative resilience of medical demand. The pre-market focus on healthcare stocks is being driven by the latest corporate reporting cycle and its emphasis on delivery rather than broad market momentum. Recent London disclosures have offered useful operational evidence, yet the wider setting remains unsettled. Energy costs, borrowing conditions and cautious consumer or corporate demand can influence the sector through different channels, so the strongest current story is not simply whether sentiment improves. It is whether company statements support the assumptions already embedded in each business narrative.<\/p>\n What Has Changed In The Reporting Conversation?<\/p>\n The current discussion around what has changed in the reporting conversation is also about management credibility. In healthcare stocks, a confident statement has limited value unless it is supported by operational milestones, cash discipline and a clear account of risks. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n are not interchangeable, but reading their latest disclosures side by side can reveal what the market is asking from the category. Detail on customers, projects, capacity, costs or regulation can narrow uncertainty even when the broader economic signal remains mixed.<\/p>\n Market liquidity changes how evidence is absorbed. Larger names in healthcare stocks may attract continuous scrutiny, while smaller peers can react more sharply when a disclosure resolves or creates uncertainty. That difference does not change the underlying analytical task. For both GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n , the substance lies in operating progress, funding capacity and the durability of customer or asset economics, rather than in the intensity of a short-lived market reaction.<\/p>\n Why Is GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n A Useful Reference Point?<\/p>\n Cost pressure reaches healthcare stocks through more than a simple inflation channel. Energy, labour, finance, logistics and specialist inputs can affect margins or project economics, while the ability to pass those costs on depends on contracts and competitive position. That is why why is gsk Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n a useful reference point has become a test of operating design. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n may have scale or diversification on its side, whereas Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n may offer greater sensitivity to a focused catalyst, leaving the quality of execution as the common point of comparison.<\/p>\n Another useful distinction concerns time horizon. Some evidence in healthcare stocks appears quickly through orders, sales or customer retention, while other outcomes depend on long development, approval or investment cycles. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n sit at different points on that spectrum. The market’s current selectivity reflects a preference for knowing what can be verified now, what depends on management execution and what remains exposed to external decisions.<\/p>\n How Do Peers Complicate The Picture?<\/p>\n A selective market tends to expose the difference between narrative momentum and disclosed progress. For healthcare stocks, how do peers complicate the picture is strongest where management has identified a concrete route from investment to durable activity. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n bring different evidence to that assessment, but neither avoids the need for disciplined capital use. The sector can remain topical even when share-price reactions diverge, because investors are testing individual claims rather than treating the category as a uniform trade.<\/p>\n There is also a governance dimension to healthcare stocks. Capital-intensive decisions, acquisitions and major partnerships can reshape risk long before they affect reported performance. The latest statements from GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n can be assessed for consistency between strategic language and day-to-day priorities. Clear accountability, realistic sequencing and transparent explanation of trade-offs tend to matter more when financing conditions are demanding and the external outlook can shift quickly.<\/p>\n What Does Operational Delivery Look Like Here?<\/p>\n Balance-sheet flexibility has become part of the editorial story around healthcare stocks. Businesses that can fund required investment while protecting day-to-day resilience occupy a different position from those dependent on frequent external capital. This does not automatically favour size, since focused operators can also preserve flexibility through partnerships, phased development or asset-light models. The contrast between GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n helps explain why what does operational delivery look like here is producing company-led outcomes rather than a simple category-wide judgement.<\/p>\n The sector’s relationship with policy deserves attention as well. Regulation, planning, taxation, procurement and competition rules can influence healthcare stocks without appearing immediately in reported trading. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n may face distinct policy channels, yet each needs a strategy capable of adapting without losing commercial focus. The current uncertainty makes policy exposure part of the company story rather than a remote background issue.<\/p>\n Why Is Cash Conversion Being Scrutinised?<\/p>\n International exposure adds another layer. Sterling movements, overseas demand, commodity pricing and foreign regulation may change reported momentum for healthcare stocks, even when the domestic UK economy is subdued. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n can therefore be influenced by a different mix of external forces from Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n . When assessing why is cash conversion being scrutinised, the useful question is whether global exposure diversifies risk or introduces fresh sensitivity, and whether management reporting makes that trade-off sufficiently visible.<\/p>\n Taken together, these factors explain why healthcare stocks can command attention without moving as a single block. drug-pipeline disclosures, half-year reporting and transaction activity are making healthcare a company-led defensive theme. The category contains businesses with different revenue engines, capital needs and sensitivities, so the live UK theme is comparative. Fresh disclosures from GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n , Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n and their quoted peers provide the evidence needed to distinguish resilience, optionality and unresolved execution risk.<\/p>\n Can Management Commentary Reset Expectations?<\/p>\n Official disclosures remain the cleanest way to test the current narrative. Trading statements, results, production reports, clinical updates and transaction notices each answer different questions, but all can show whether healthcare stocks are moving from intention to delivery. The latest communication from GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n or Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n should be read for changes in tone, priorities and risk language as much as for headline claims. That approach is particularly important in a pre-market edition, when verified corporate evidence is firmer than speculation about the coming session.<\/p>\n Market liquidity changes how evidence is absorbed. Larger names in healthcare stocks may attract continuous scrutiny, while smaller peers can react more sharply when a disclosure resolves or creates uncertainty. That difference does not change the underlying analytical task. For both GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n , the substance lies in operating progress, funding capacity and the durability of customer or asset economics, rather than in the intensity of a short-lived market reaction.<\/p>\n Where Are Market Assumptions Most Exposed?<\/p>\n The main risk to where are market assumptions most exposed is that the wider environment changes faster than company plans. A renewed energy shock, weaker demand, tougher financing or regulatory delay could alter the sector’s economics. Equally, improved supply conditions, easing cost pressure or a credible operational milestone could reduce uncertainty. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n will not respond identically, which is why the category’s relevance today rests on dispersion as much as on a shared macro theme.<\/p>\n Another useful distinction concerns time horizon. Some evidence in healthcare stocks appears quickly through orders, sales or customer retention, while other outcomes depend on long development, approval or investment cycles. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n sit at different points on that spectrum. The market’s current selectivity reflects a preference for knowing what can be verified now, what depends on management execution and what remains exposed to external decisions.<\/p>\n What Should The Next Updates Clarify?<\/p>\n For healthcare stocks, what should the next updates clarify cannot be separated from the latest corporate reporting cycle and its emphasis on delivery rather than broad market momentum. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n provides one listed reference point, while Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n shows how a different operating model can respond to the same pressure. The relevant distinction is the source of revenue visibility: contracted, regulated or recurring income tends to be read differently from project-led, cyclical or discretionary exposure. Recent company communication therefore matters most when it explains the bridge between present trading and the strategic promise attached to the business.<\/p>\n There is also a governance dimension to healthcare stocks. Capital-intensive decisions, acquisitions and major partnerships can reshape risk long before they affect reported performance. The latest statements from GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n can be assessed for consistency between strategic language and day-to-day priorities. Clear accountability, realistic sequencing and transparent explanation of trade-offs tend to matter more when financing conditions are demanding and the external outlook can shift quickly.<\/p>\n The sector’s relationship with policy deserves attention as well. Regulation, planning, taxation, procurement and competition rules can influence healthcare stocks without appearing immediately in reported trading. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n may face distinct policy channels, yet each needs a strategy capable of adapting without losing commercial focus. The current uncertainty makes policy exposure part of the company story rather than a remote background issue. For this article’s focus, Spire Healthcare Group Healthcare<\/a><\/p>\n 218.00 -1.000<\/p>\n \u2193 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n adds a further quoted comparison: its exposure is shaped by a different combination of customers, assets and strategic choices. That contrast keeps the analysis grounded in the category’s present evidence rather than in a generic market label.<\/p>\n Another useful distinction concerns time horizon. Some evidence in healthcare stocks appears quickly through orders, sales or customer retention, while other outcomes depend on long development, approval or investment cycles. GSK Healthcare<\/a><\/p>\n 1916.50 -39.500<\/p>\n \u2193 Last Updated at: 2026-07-17T15:40:00Z<\/p>\n and Hikma Pharmaceuticals Healthcare<\/a><\/p>\n 1561.00 +10.000<\/p>\n \u2191 Last Updated at: 2026-07-17T15:35:00Z<\/p>\n sit at different points on that spectrum. The market’s current selectivity reflects a preference for knowing what can be verified now, what depends on management execution and what remains exposed to external decisions. For this article’s focus, Spire Healthcare Group
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\nRecent disclosures from GSK
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\nFunding flexibility, cost control and management execution are separating quoted businesses within the category.<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (lse:gsk)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:SPI)<\/a><\/p>\n
\n Spire Healthcare Group Plc (LSE:SPI)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.457%<\/p>\n
\n (LSE:GSK)<\/a><\/p>\n
\n GSK plc (LSE:GSK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 2.019%<\/p>\n
\n (LSE:HIK)<\/a><\/p>\n
\n Hikma Pharmaceuticals PLC (LSE:HIK)
\n <\/a><\/p>\n
\n GBX<\/p>\n
\n 0.645%<\/p>\n
\n (LSE:SPI)<\/a><\/p>\n